latest update:
[TrialBase DB]

trial summary · NCT06406465

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Trial record from the TrialBase DB dataset, status RECRUITING, condition Carcinoma, Neuroendocrine, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06406465phase PHASE2enrollment 60start 2026-11-04

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Background: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head. One drug (belinostat), combined with 2 other drugs (etoposide and cisplatin), is approved to treat HGNEC. But some people may have a gene variant that affects how quickly their body gets rid of the drug; these people may do better with different dosages of belinostat. Objective: To test higher or lower doses of belinostat based on gene variants in people with HGNEC. Eligibility: People aged 18 years and older with HGNEC. Design: Participants will be screened. They will have a physical exam with blood tests. Some blood will be used for genetic testing. They will have imaging scans and a test of their heart function. Samples of tumor tissue may be collected. All 3 study drugs (belinostat, etoposide, cisplatin) are given through a tube attached to a needle inserted into a vein. Treatment will be given in 21-day cycles. For cycles 1 through 6: Participants will come to the clinic for the first 4 days. They will be given all 3 drugs. Imaging scans and other tests will be repeated. Each visit will last 4 to 8 hours. After cycle 6: Participants may continue treatment with belinostat alone. They will come to the clinic for the first 3 days of each cycle. They may continue treatment for up to 5 years if the drug is helping them. Participants will have a follow-up visit 30 days after their last dose of belinostat. Then they will receive follow-up visits by phone or email every 3 to 6 months.

Source record: https://clinicaltrials.gov/study/NCT06406465

Facts

registry idNCT06406465
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionCarcinoma, Neuroendocrine
sponsorNational Cancer Institute (NCI)
sponsor classNIH
enrollment60
start date2026-11-04
primary completion2027-07-30
completion2028-07-30
results postednot reported

Conditions

  • Carcinoma, Neuroendocrine
  • Tumor, Neuroendocrine
  • Tumors, Neuroendocrine
  • Neuroendocrine; Carcinoma
  • Small Cell; Receptors

Interventions

  • Belinostat
  • Cisplatin
  • Etoposide

Countries

  • United States

Intervention types: DRUG

Work with this record